Cargando…

Triple‐negative breast carcinomas are a heterogeneous entity that differs between young and old patients

OBJECTIVE: To compare the frequency and immunohistochemical profiles of triple‐negative breast carcinomas in younger and older women. METHODS AND RESULTS: We selected patients diagnosed with triple‐negative breast carcinomas. The groups examined were women who were 35 years old or younger between 19...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carvalho, Filomena M, Bacchi, Livia M, Santos, Priscila P C, Bacchi, Carlos E
Formato:	Texto
Lenguaje:	English
Publicado:	Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2010
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2972605/ https://www.ncbi.nlm.nih.gov/pubmed/21120307 http://dx.doi.org/10.1590/S1807-59322010001000019

Ejemplares similares

Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ
por: Aguiar, Fernando N., et al.
Publicado: (2013)

Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil
por: Carvalho, Filomena M, et al.
Publicado: (2014)

The role of intratumoral lymphovascular density in distinguishing primary from secondary mucinous ovarian tumors
por: de Lacerda Almeida, Bernardo Gomes, et al.
Publicado: (2014)

Neuroendocrine tumors involving the gastroenteropancreatic tract: a clinicopathological evaluation of 773 cases
por: Estrozi, Bruna, et al.
Publicado: (2011)

A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns
por: Tzikas, Anna-Karin, et al.
Publicado: (2020)

Pediatric lymphomas in Brazil
por: Gualco, Gabriela, et al.
Publicado: (2010)

Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients
por: Bacchi, Carlos E., et al.
Publicado: (2012)

Triple-negative breast cancer: from none to multiple therapeutic targets in two decades
por: Carvalho, Filomena Marino
Publicado: (2023)

Heterogeneity at the invasion front of triple negative breast cancer cells
por: Aw Yong, Koh Meng, et al.
Publicado: (2020)

Atypical Hemolytic Uremic Syndrome Recurrence after Renal Transplantation: C3-Glomerulonephritis as an Initial Presentation
por: Bouatou, Yassine, et al.
Publicado: (2015)

Molecular heterogeneity in adjacent cells in triple-negative breast cancer
por: Huebschman, Michael L, et al.
Publicado: (2015)

Evaluation of triple negative breast cancer with heterogeneous immune infiltration
por: Quintana, Ángela, et al.
Publicado: (2023)

L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion
por: de Freitas, Daniela, et al.
Publicado: (2018)

Integrative analysis of the inter-tumoral heterogeneity of triple-negative breast cancer
por: Chiu, Alec M., et al.
Publicado: (2018)

Phenotypic analysis of breast cell lines – triple negative cells vs expressing hormonal receptors
por: Laranjo, Mafalda, et al.
Publicado: (2010)

Predicting response and survival in chemotherapy-treated triple-negative breast cancer
por: Prat, A, et al.
Publicado: (2014)

Toward a common clinical lexicon of consciousness
por: Bacchi, Stephen, et al.
Publicado: (2023)

Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers
por: Wang, Lei, et al.
Publicado: (2020)

Radiogenomic analysis reveals tumor heterogeneity of triple-negative breast cancer
por: Jiang, Lin, et al.
Publicado: (2022)

Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer
por: Kudelova, Eva, et al.
Publicado: (2022)

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
por: O’Shaughnessy, Joyce, et al.
Publicado: (2022)

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors
por: Bartelink, Imke H., et al.
Publicado: (2017)

Fallopian tube origin of supposed ovarian high‐grade serous carcinomas
por: Diniz, Patricia Martini, et al.
Publicado: (2011)

Clinicopathological characteristics of endometrial carcinomas according to DNA mismatch repair protein status
por: de Freitas, Daniela, et al.
Publicado: (2023)

Prognosis in triple‐negative apocrine carcinomas of the breast: A population‐based study
por: Wu, Wenyu, et al.
Publicado: (2019)

Prognostic value of podoplanin expression in intratumoral stroma and neoplastic cells of uterine cervical carcinomas
por: Carvalho, Filomena M, et al.
Publicado: (2010)

Functional Heterogeneity of the Young and Old Duplicate Genes in Tung Tree (Vernicia fordii)
por: Jiang, Lan, et al.
Publicado: (2022)

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
por: Bareche, Y, et al.
Publicado: (2018)

Molecular analyses of triple-negative breast cancer in the young and elderly
por: Aine, Mattias, et al.
Publicado: (2021)

Heterogeneity derived from (18)F‐FDG PET/CT predicts immunotherapy outcome for metastatic triple‐negative breast cancer patients
por: Xie, Yizhao, et al.
Publicado: (2022)

Outcome for Patients with Triple-Negative Breast Cancer Is Not Dependent on Race/Ethnicity
por: Chu, Quyen D., et al.
Publicado: (2012)

Identification of ERBB Pathway-Activated Cells in Triple-Negative Breast Cancer
por: Cho, Soo Young
Publicado: (2019)

Development of an immune-related prognostic biomarker for triple-negative breast cancer
por: Zhang, Yan, et al.
Publicado: (2022)

Methylation profile of triple-negative breast carcinomas
por: Branham, M T, et al.
Publicado: (2012)

In vivo pulmonary metastatic profile of breast cancer cell lines expressing hormonal receptors versus triple negative
por: Carvalho, M João, et al.
Publicado: (2010)

Phenotypic Heterogeneity of Triple-Negative Breast Cancer Mediated by Epithelial–Mesenchymal Plasticity
por: Kvokačková, Barbora, et al.
Publicado: (2021)

Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications
por: Asleh, Karama, et al.
Publicado: (2022)

Challenges for Triple Negative Breast Cancer Treatment: Defeating Heterogeneity and Cancer Stemness
por: Mahmoud, Rinad, et al.
Publicado: (2022)

Editorial: Triple-negative breast cancer: Heterogeneity, tumor microenvironment and targeted therapy
por: Deng, Xiyun, et al.
Publicado: (2022)

Clinicopathological factors associated with novel prognostic markers for patients with triple negative breast cancer
por: Badowska-Kozakiewicz, Anna M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rhhgdppfam1vvlh6a1n57ek9ps